Charles Fuenzalida, MD
Cardiovascular Disease · Aurora, CONPI 1730175688
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,075 of the $29,943 with a category attached, or 70.4%. Medical Device Business Services, Inc. accounts for 68.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2024 at $9,538 and has fallen 57.0% since, to $4,097 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $107.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$20K
- Boston Scientific$2K
- Biosense Webster, Inc.$2K
- Medtronic$601
- Impulse Dynamics (USA) Inc.$379
- Sanofi-aventis U.S. LLC$378
- plus $4K from 34 others
Across 23 payments — averaging $173.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$4K
What the payments were for
- Consulting fees$21,07570%
- Travel & lodging$2,1607%
- Food & beverage$6,70822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$21,194
- Rhythmia Mapping System$1,309
- Carto 3 System$998
- Barostim Neo System$227
- Ensite Cardiac Mapping System$174
- remede System$149
- OPTIMIZER SMART SYSTEM$144
- Acticor 7 VR-T DX$143
- OPTIMIZER$141
- XARELTO$139
- RESONATE$123
- GENERAL TACHY$109
- Visia AF$102
- Watchman$102
How this compares
$29,943 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 668 | $801,476 |
| XareltoRivaroxaban | 139 | $197,820 |
| MultaqDronedarone Hcl | 95 | $113,205 |
| JardianceEmpagliflozin | 81 | $88,403 |
| Repatha SureclickEvolocumab | 39 | $39,905 |
| FarxigaDapagliflozin Propanediol | 38 | $32,437 |
| EntrestoSacubitril/Valsartan | 17 | $24,951 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 37 | $11,361 |
| Dofetilide | 53 | $8,486 |
| SotalolSotalol Hcl | 186 | $6,411 |
| Verapamil Er PmVerapamil Hcl | 19 | $5,366 |
| Flecainide Acetate | 97 | $4,642 |
| Digoxin | 51 | $3,576 |
| Propafenone Hcl ErPropafenone Hcl | 21 | $3,516 |
| Eplerenone | 35 | $2,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $366 | $801,476668 claims |
| Johnson & JohnsonXarelto | $331 | $197,820139 claims |
| Sanofi-aventis U.S. LLCMultaq | $378 | $113,20595 claims |
| Boehringer IngelheimJardiance | $168 | $88,40381 claims |
| NovartisEntresto | $324 | $24,95117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Aurora
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- William SauerAurora$365K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Edward GillAurora$96K
- Joseph AdewumiAurora$61K
- Christina HealyAurora$25K
- Sundeep ViswanathanAurora$21K
- Nelson PragerAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.